

OPDIVO®

(nivolumab)

Patient Alert Card

**This card
contains important information.**

Please carry this card with you
at all times to inform healthcare
professionals that you are receiving
treatment with

- ☐ OPDIVO® or
- ☐ OPDIVO® in combination with
YERVOY® (ipilimumab).



My Doctor's Contact Information

(who prescribed OPDIVO® or OPDIVO®
in combination with YERVOY®)

Name of Doctor:

Office Phone:

Out-of-Hours Phone:

My Contact Information

My Name:

My Phone Number:

Emergency Contact:
Name:

Phone Number:

Important Information for Patients



**If you have any signs or symptoms,
tell your doctor right away.**



IMPORTANT

■ OPDIVO® treatment may increase the risk of serious or even life-threatening immune-related side-effects, which may affect different parts of the body, for example:

- **Chest (heart and lungs):** breathing difficulties, cough, wheeze, chest pain, irregular heartbeat, palpitations (increased awareness of your heartbeat)
- **Gut (stomach and bowels):** diarrhoea (watery, loose or soft stools), blood or mucus in stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area
- **Liver:** eye or skin yellowing (jaundice), pain on the right side of your stomach area
- **Kidney:** change in amount and/or frequency of urine
- **Hormone-producing glands (including Diabetes):** headaches, blurry or double vision, fatigue (tiredness), weight changes, behavioural changes (e.g. lower sex drive, irritability or forgetfulness), excessive thirst, increased appetite with weight loss, weakness, drowsiness, depression, irritability, feeling unwell, change in amount and/or frequency of urine)
- **Skin:** rash, itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules
- **Other:** weakness, fatigue (tiredness), decreased appetite, nausea, vomiting, tingling or numbness in arms and legs, difficulty walking, fever, swollen lymph nodes, headache, seizures, stiff neck, confusion, drowsiness, muscle pain, stiffness, dark urine, eye pain or redness, blurry vision, or other vision problems



IMPORTANT

- Tell your doctor of previous medical conditions, including if you have had a stem cell transplant that used donor stem cells (allogeneic).
- Early assessment and management of side effects by your doctor reduces the likelihood that treatment with OPDIVO® or OPDIVO® in combination with YERVOY® will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last infusion.

For more information, read the OPDIVO® Package Leaflet or call Medical Information on phone: 0800/0752002, email: medwiss.info@bms.com or www.bmsmedinfo.de.

Reporting suspected Adverse Reactions

Please report side effects to the Paul-Ehrlich-Institute at phone: +49 (0)6103 770 or www.pei.de or to Bristol Myers Squibb Medical Information using the contact details above.



IMPORTANT Information for Healthcare Professionals

- This patient is treated with **OPDIVO®** or **OPDIVO® in combination with YERVOY®**.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise the risk of life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the OPDIVO® Summary of Product Characteristics (SmPC) or call Medical Information on phone: 0800/0752002, email: medwiss.info@bms.com or www.bmsmedinfo.de for more information.



The healthcare professional treating this patient with OPDIVO® or OPDIVO® in combination with YERVOY® should complete the 'My Doctor's Contact Information' section of this Patient Alert Card.

Doctor's
contact information

© Bristol Myers Squibb, 05/2020
APPRO Date Paul-Ehrlich-Institute:
28-May-2020
APPRO No. BMS DE: 7356DE20SD00736-01
Art. 6229, Version 12.0, 05/2020

 Bristol Myers Squibb™